Methylphenidate (MPH), a first-line treatment for attention-deficit/hyperactivity disorder (ADHD), is increasingly debated for its use for cognitive enhancement by university/college students without an ADHD diagnosis. However, current knowledge relies on self-reported data, while consumption-based data remain limited. This wastewater-based epidemiology study assessed MPH consumption at population level by measuring ritalinic acid (a urinary MPH consumption biomarker) in influent wastewater…
